FDA cleared Bioretec's ActivaScrew Cannulated COM on September 8. The headless screw is made from self-reinforced PLGA and is indicated for fixation of bone and osteochondral fractures, osteotomies, arthrodeses and bone grafts in the hand, the non-diaphyseal arm and forearm, the foot and the non-diaphyseal ankle, in skeletally mature patients with appropriate immobilization.

The Finnish company already sells the ActivaScrew line and says more than 500,000 Activa implants have been distributed. CEO Sarah van Hellenberg Hubar-Fisher said the headless design matches what US surgeons prefer, and called the clearance part of the 2026 commercialization plan.

The indication statement is worth reading closely if you are drafting your own. Every anatomic site is enumerated and the diaphysis is carved out twice. That is what a predicate-driven orthopedic clearance looks like when the sponsor keeps the claim narrow enough to avoid new bench or clinical data.